Efficacité et sécurité des DMARD biologiques : Une revue systématique de la littérature pour la mise à jour 2022 des recommandations ASAS-EULAR pour la prise en charge de la spondylarthrite axiale
Ann Rheum Dis 2022; online ahead of print doi:10.1136/ard-2022-223298
New evidence supports the efficacy and safety of TNFi (originators/biosimilars) and IL-17i in r-axSpA and nr-axSpA. This systematic literature review was conducted to inform the taskforce of the 2022 update of the ASAS-EULAR recommendations.
Interestingly, IL-23i failed to show relevant effects. Observational studies are needed to confirm long-term IL-17i safety. This review informed the 2022 ASAS-EULAR management recommendations for axSpA, highlighting new evidence on efficacy and safety of existing and new bDMARDs
Keywords:
